Evaluation of CpG Island Methylator Phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin

Benzer Materyaller

• Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
  Yazar:: Pectasides, Dimitrios, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
  Yazar:: Pentheroudakis, George, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases
  Yazar:: Cohen, Stacey A., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research
  Yazar:: Kotoula, Vassiliki, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome
  Yazar:: Pentheroudakis, George, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)